Internal Medicine · Tampa, FL
NPI
1154697738
Since 2012
Specialty
Internal Medicine
Code 207R00000X
Group practices
1
Medicare group memberships
Hospitals
1
Hospital affiliations
12902 Usf Magnolia Dr
Tampa, FL, 33612
Phone (813) 745-7365
Groups this clinician bills Medicare through
Medicare paid, 2024
$28K
323 services
Medicare patients, 2024
207
Average age 74
Drug cost, 2024
$13.2M
910 prescriptions
Company payments, 2025
$67K
From 10 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Andrew T Kuykendall was code 99214 (office e&m - established), 133 times for 116 patients. In total Andrew T Kuykendall billed 323 services in 11 codes, and Medicare paid $28K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2025-12-16.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Facility | 133 | 116 | $65.88 | $8,762 |
| 99215 Office E&M - Established | Facility | 72 | 57 | $105.98 | $7,630 |
| 99205 Office E&M - New | Facility | 51 | 51 | $127.42 | $6,499 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Facility | 24 | 23 | $12.97 | $311 |
| 99214 Office E&M - Established | Office | 20 | 19 | $100.59 | $2,012 |
| 99215 Office E&M - Established | Office | 14 | 12 | $142.06 | $1,989 |
By year: 2022 $39K for 391 services; 2023 $39K for 426 services; 2024 $28K for 323 services.
Medicare prescription drug claims, 2024
In 2024, the drug Andrew T Kuykendall prescribed most often to Medicare patients was Jakafi (Ruxolitinib Phosphate), with 381 prescriptions and refills. In total Andrew T Kuykendall wrote 910 Medicare prescriptions that cost $13.2M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Jakafi Ruxolitinib Phosphate | 381 | 399 | 53 | $6.9M |
| Hydroxyurea Generic | 102 | 195 | 38 | $2,424 |
| Ojjaara Momelotinib Dihydrochloride | 75 | 75 | 13 | $2.1M |
| Besremi Ropeginterferon Alfa-2b-Njft | 54 | 54 | Under 11 | $872K |
| Ayvakit Avapritinib | 51 | 51 | Under 11 | $2.0M |
| Pegasys Peginterferon Alfa-2a | 42 | 42 | Under 11 | $171K |
| Eliquis Apixaban | 36 | 44 | Under 11 | $25K |
| Allopurinol Generic | 30 | 54 | 12 | $95.47 |
| Vonjo Pacritinib Citrate | 21 | 21 | Under 11 | $549K |
| Venclexta Venetoclax | 18 | 18 | Under 11 | $59K |
Brand drugs: 702 claims; generic drugs: - claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Andrew T Kuykendall $67K ($67K in general payments such as food, travel and fees and $143 for research) from 10 companies. The largest payer was Merck Sharp & Dohme LLC with $18K.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.